Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
  • Science
      • All Events
        • Cardiovascular
        • Diabetes
        • Obesity
        • Sleep
      • Immunology
      • Neuroscience
      • Oncology
      • Diabetes
      • Immunology
      • Neuroscience
      • Obesity
      • Oncology
    • Trial Imagery
    • Investigational Drugs
    • External Link Independent Research
    • External Link Clinical Trials
  • Medical Information
  • Medical Education
  • Chat Contact Us
Lilly

You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.

Cardiovascular Journal Publications

This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

For all other requests, please visit our Contact Lilly services.

Lyumjev® (insulin lispro - aabc)

Full Prescribing Information

Ultra Rapid Lispro (Lyumjev®) Shortens Time to Recovery from Hyperglycaemia Compared to Humalog® in Individuals with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
Published Date: October 9, 2023
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents, and adults with type 1 diabetes mellitus
Published Date: May 11, 2023
An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths.
Published Date: November 3, 2022
Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
Published Date: June 14, 2022
Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Published Date: January 25, 2022
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study
Published Date: January 25, 2022

Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
Published Date: September 25, 2023
Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
Published Date: December 1, 2021
Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study
Published Date: October 4, 2021

Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial
Published Date: September 1, 2023
Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range
Published Date: April 11, 2023
Efficacy and safety of ultra rapid lispro (URLi) versus Lispro in children and adolescents with type 1 diabetes: PRONTO-Peds
Published Date: September 9, 2022
Ultra Rapid Lispro Improves Postprandial Glucose Control Versus Lispro in Combination With Insulin Glargine/Degludec in Adults With Type 2 Diabetes: A Prospective, Randomized, Double-Blind Phase 3 Trial
Published Date: August 4, 2022
Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study.
Published Date: July 4, 2022
Long-term Efficacy and Safety of Ultra Rapid Lispro in Japanese Patients With Type 1 Diabetes: Subpopulation Analysis of the 52-Week PRONTO-T1D Study.
Published Date: September 1, 2021

The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes.
Published Date: May 15, 2023
Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
Published Date: May 11, 2023
Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009─2020
Published Date: April 17, 2023
Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
Published Date: February 16, 2023
Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
Published Date: September 2, 2022
Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.
Published Date: May 20, 2022

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap
     

    This site is intended for US Healthcare Professionals only.

    4.0.95 06/2026 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2026. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    Facebook X LinkedIn
    Lilly